Mechelen, Belgium — October 30, 2025 — Leads & Copy — Galapagos NV (Euronext & NASDAQ: GLPG) has announced changes to its Board of Directors to enhance long-term governance and strategic continuity. Seasoned biopharma executive Dr. Neil Johnston has been appointed as Non-Executive Independent Director, effective November 1, 2025. In addition, Devang Bhuva, Senior Vice President of Corporate Development and Alliance Management at Gilead, has been appointed as Non-Executive Non-Independent Director, also effective November 1, 2025.
Non-Executive Independent Directors Dr. Elisabeth Svanberg and Dr. Susanne Schaffert, along with Non-Executive Non-Independent Director and current CFO of Gilead, Andrew Dickinson, will step down, effective November 1, 2025.
Jérôme Contamine, Chair of the Board of Galapagos, welcomed Neil and Devang, noting their financial leadership and strategic transaction expertise. Henry Gosebruch, CEO of Galapagos, looks forward to working with the new directors to deliver enhanced stakeholder value through business development strategy execution.
Dr. Neil Johnston currently serves as Non-Executive Chair at Qureight Limited, and Devang Bhuva serves as Senior Vice President at Gilead.
Investor Relations Contact:
Glenn Schulman
+1 412 522 6239
ir@glpg.com
Corporate Communications Contact:
Marieke Vermeersch
+32 479 490 603
media@glpg.com
Source: Galapagos NV
